Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Design Therapeutics (DSGN) Cash from Investing Activities (2020 - 2021)

Design Therapeutics' Cash from Investing Activities history spans 2 years, with the latest figure at -$50.1 million for Q4 2021.

  • For Q4 2021, Cash from Investing Activities fell 2605.46% year-over-year to -$50.1 million; the TTM value through Dec 2021 reached -$53.6 million, down 59.84%, while the annual FY2025 figure was $22.9 million, 47.87% down from the prior year.
  • Cash from Investing Activities for Q4 2021 was -$50.1 million at Design Therapeutics, down from -$5.0 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $23.0 million in Q1 2021 and bottomed at -$50.1 million in Q4 2021.